Adam Kibel, MD, is Professor of Surgery at Harvard Medical School. In addition to being Chief of Urology and BWH/DFCI, Dr. Kibel currently serves as Co-Leader of the Dana Farber/Harvard Cancer Center Prostate Cancer Program, Chairman of the Harvard Program in Urology (Longwood), Program Director of the Harvard Program in Urology (Longwood). He serve in multiple leadership roles nationally including vice chair of the AUA guidelines panel for lethal prostate cancer, the PDQ Cancer Genetics Editorial Advisory Board, and the NCCN-Prostate Screening Guidelines Committee.
Dr. Kibel is a clinical and translational researcher. Current research focuses on the identification of molecular markers of urologic tumors, adjuvant and neoadjuvant approaches to treatment of aggressive disease, and improved imaging of patients with urologic malignancies. A particular focus has been using sequencing of germline DNA to look for rare variants linked to lethal prostate cancer risk. He has been funded by the National Cancer Institute, American Cancer Society, American College of Surgeons, and the American Foundation for Urologic Disease for research in this space. He has co-authored over 200 peer reviewed publications including papers in leading journals such as Science, Nature, JAMA, New England Journal of Medicine, Cancer Research and Journal of Clinical Oncology.
Dr. Kibel graduated from Cornell University, College of Arts and Sciences i 1987 and then Cornell University School of Medicine in 1991 as a member of AOA. He did his surgical and urological residencies at Brigham and Women’s Hospital from 1991-1997. During his residency he spent a year working with Dr. William Kaelin at the DFCI elucidating the functions of the VHL tumor suppressor gene. Following his residency, he then completed a 2 year post doc at the Brady Urologic Institute at Johns Hopkins in with Dr. William Isaacs examining the genetics of prostate cancer.